( July 10, 2026, 10:56 AM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel on July 9 saw no error in a Delaware federal judge’s decision to grant judgment as a matter of law (JMOL) on invalidity as to multiple patent claims asserted by a biopharmaceutical company that accused AstraZeneca Pharmaceuticals LP and a related entity of infringing its cancer treatment patents; the panel agreed with the judge that the asserted patents disclosed only broad projected ranges of dosages without clearly explaining how to determine a therapeutic dosage....